Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 1/2 1

Status

Terminated 2Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Leukemia, Myeloid, Acute 54Multiple Myeloma 45Lymphoma 44Lymphoma, Non-Hodgkin 41Leukemia 38Precursor Cell Lymphoblastic Leukemia-Lymphoma 35Hodgkin Disease 35Myelodysplastic Syndromes 34Lymphoma, Mantle-Cell 20Lymphoma, Large B-Cell, Diffuse 19Leukemia, Myelogenous, Chronic, BCR-ABL Positive 19Leukemia, Lymphocytic, Chronic, B-Cell 16Burkitt Lymphoma 16Breast Neoplasms 13Neoplasms, Plasma Cell 11Recurrence 10Lymphoma, Follicular 10Hematologic Neoplasms 9Anemia, Refractory, with Excess of Blasts 9Lymphoma, B-Cell, Marginal Zone 8Neuroblastoma 7Myeloproliferative Disorders 7Lymphoma, Large-Cell, Immunoblastic 7Central Nervous System Neoplasms 7Blast Crisis 7Neoplasms 6Lymphoma, T-Cell 6Leukemia, Myelomonocytic, Juvenile 6Leukemia, Myelomonocytic, Chronic 6Graft vs Host Disease 6

Interventions

Dexamethasone 23Melphalan 18Cyclophosphamide 12Filgrastim 10Bortezomib 10Calcium Dobesilate 8Peripheral Blood Stem Cell Transplantation 7daratumumab 6Lenalidomide 6pomalidomide 5dexamethasone acetate 3birtamimab 3Thalidomide 3Radiotherapy 3Interferon-alpha 3Granulocyte Colony-Stimulating Factor 3sargramostim 2isatuximab 2dexamethasone 21-phosphate 2belantamab mafodotin 2Focal Adhesion Protein-Tyrosine Kinases 2Etoposide 2Epoetin Alfa 2Doxycycline 2Busulfan 2siltuximab 1pegfilgrastim 1ixazomib 1fludarabine phosphate 1elotuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Immunoglobulin Light-chain Amyloidosis × Granulocyte Colony-Stimulating Factor × Clear all
NCT00651937 2020-01-14

Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden

M.D. Anderson Cancer Center

Phase 2 Completed
80 enrolled 7 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma

NCT00681044 2017-04-28

HD Melphalan and SCT in Patients With IGDD or LCDD

Boston Medical Center

Phase 2 Terminated
5 enrolled 7 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma

NCT00075608 2017-01-27

2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis

Boston Medical Center

Phase 2 Terminated
12 enrolled 6 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡